A licence and distribution agreement has been formed between Grünenthal and Mundipharma, which will see Mundipharma market and distribute Tramal (tramadol) in China from the beginning of May. Read more


AYOXXA Biosystems and Grünenthal have been using AYOXXA's protein multiplexing technology platform to analyse an inflammation marker at very low concentrations released from human cells following treatment in cell culture experiments. Read more


The research-based international pharmaceutical company Grünenthal will deploy the PAS-X Process Development package. The group is a leader in the field of pain therapies and invests more than a quarter of its revenues in R&D. Read more